Hepatitis Foundation of Ghana

Email

info@hepatitisghana.org

Phone

M: +233-20-826-9214

Web

www.hepatitisghana.org

Address

PO Box GP 21325, Accra 21325 Ghana
About Hepatitis Foundation of Ghana

Hepatitis Foundation of Ghana is a patient’s organization and non-profit, non-governmental organization (NGO) registered in Ghana. It seeks to promote awareness of the prevalence and incidence of viral hepatitis in Ghana, and to educate the public in the prevention of the spread of the virus and the available treatment options. We also provide care and psychosocial support to the infected and affected people and their families. In addition, it seeks to serve as the primary source of information for patients and their families.

VISION

Our vision is to eliminate new viral hepatitis infections and improve the quality of life for individuals living with chronic hepatitis B and C.

MISSION

The mission of the Hepatitis Foundation of Ghana is establishing a uniform and fair approach to the effective prevention and comprehensive management of Hepatitis B among people and their families in Ghana.

OUR CORE VALUES

Competence with responsibility and professionalism are our core values. With integrity and being transparent in everything we do, we accept responsibility for our collective and individual actions. Our focus is to work effectively to serve individuals living with viral hepatitis and the larger community in Ghana. Having respect for all, we affirm the dignity and contribution of community participants, development partners, donors and staff as we work for the better of people living with viral hepatitis in Ghana.

OBJECTIVES

  • To prevent Hepatitis B spread amongst people or patients and their families.
  • To provide treatment, care support and psychosocial support for infected and affected people and their families.
  • To provide protection from stigma and discrimination in the houses, churches, market places and offices living with or affected by Hepatitis B.
  • Promoting disease awareness, supporting immunization and treatment initiatives, and serving as the primary source of information for patients and their families and the general public.
  • To empower young people, to promote their rights and to inform them about how Hepatitis cannot be transmitted, and how they can protect themselves.
  • To draw the attention of people in general and those in positions of authority in particular to accept the reality of Hepatitis in our communities, and to recognize the rights of people living with Hepatitis.
  • To reject myths and misconceptions, and fight unnecessary Hepatitis discrimination

Sign up to receive updates from WHA

Name(Required)
I would like to hear about(Required)

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Hepatitis and PWID/harm reduction 

 

11:35 – 11:40  

Chair: WHO – Intro and set the scene.  

 

11:40 – 11:55  

Co-chair:  EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe. 

 

11:55 – 12:00 

ID 29: Ema Pos (not yet registered) 

Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation. 

 

12:05 – 12:10  

ID 152: Brian Conway (Registered in person) 

Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.

 

12:10 – 12:15 

ID 212: Jasmine West (not yet registered) 

Title: From lived experience to lived expertise: a syndemic approach. 

 

12:15 – 12:20 

ID: 299 Mercy Nyakowa (Registered in person) 

Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya 

 

12:20 – 12:25 

ID: 133 Nalinikanta Rajkumar (Registered in person) 

Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?  

 

12:25 – 12:30 

Q&A and closing remarks   

tHIS

 

IS 

 

BEN’S

 

 

 

BIG 

 

 

TEST

effective case finding strategies

Supported by Vir Biotechnology, Inc

During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.

Session Agenda

14:40 – 14:45    

Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)

14:45 – 15:05   

Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology

15:05 – 15:10    

Final remarks and close